Skip to content

Clinical trial to study the effect of Nimba Patra kwath Dhawan in the management of Dushta vrana with special reference to Eusol OF NIMBA PATRA KWATH DHAWAN IN THE MANAGEMENT OF DUSHTA VRANA WITH SPECIAL REFERENCE TO EUSOL.

Randomised controlled open clinical study to study the efficacy of Nimba Patra Kwath Dhawan in the management of Dushta vrana with special reference to Eusol. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/059203
Enrollment
60
Registered
2023-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified Health Condition 2: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

None listed

Sponsors

Dr Irza Ayyub Pathan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having signs and symptoms of Dushta Vrana(Infected wound) Dushta vrana within Size length up to 5cm, Depth up to 2cm.

Exclusion criteria

Exclusion criteria: Patient suffering from major illness like cirrhosis, Ascites, Renal failure DM, TB, Leprosy, pregnancy, Jaundice, Varicosity, HIV Patient with malignancy. Bleeding disorder (increased BT and CT) TAO Diabetic wounds Multiple wounds

Design outcomes

Primary

MeasureTime frame
Is Nimba Patra kwath effective in the management of Dushta Vrana.Timepoint: 7 days

Secondary

MeasureTime frame
1)Study the effect of Nimba Patra kwath on Vedana, Strav, Kandu, Varna,Gandha, slough & tenderness in Dushta Vrana 2)Study the properties of Nimba Patra kwath like ShodhanTimepoint: 7 days

Countries

India

Contacts

Public ContactDr Naimish Kishor Saraf

Siddhakala Ayurveda Mahavidyalaya Sangamner

naimishsaraf@gmail.com9766786123

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026